Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 47 Thorndike St Ste B1-1 CAMBRIDGE MA 02141-1799 |
Tel: | N/A |
Website: | https://www.leaptx.com |
IR: | See website |
Key People | ||
Christopher K. Mirabelli Chairman of the Board | Douglas E. Onsi President, Chief Executive Officer, Director | Augustine J. Lawlor Chief Operating Officer |
Jason Baum Chief Scientific Officer | Christine Granfield Vice President, Head - Regulatory Affairs and Quality | Mark O'Mahony Chief Manufacturing Officer | Cynthia Sirard Chief Medical Officer |
Business Overview |
Leap Therapeutics, Inc. is a biotechnology company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. DKK1 modulates the Wnt/Beta-catenin and PI3kinase/AKT signaling pathways and promotes tumor proliferation, metastasis, angiogenesis, and in mediating an immune suppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells and downregulating NK cell ligands on tumor cells. The Company's pipeline includes FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Claudin18.2 regulates barrier properties and contributes to cell-to-cell adhesion. It also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15. |
Financial Overview |
For the fiscal year ended 31 December 2023, Leap Therapeutics Inc revenues was not reported. Net loss increased 49% to $81.4M. Higher net loss reflects General and Administrative - Balancing increase of 24% to $11.3M (expense), Australian research and development ince decrease of 46% to $1.1M (income), Stock-based Compensation in R&D increase of 4% to $2.6M (expense). |
Employees: | 54 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $0.53M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$57.44M as of Dec 31, 2023 |
Net annual income (TTM): | -$81.41M as of Dec 31, 2023 |
Free cash flow (TTM): | -$43.75M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 25,600,137 as of Mar 13, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |